Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid

CompletedOBSERVATIONAL

Enrollment

133,331

Participants

Timeline

Start Date

October 12, 2018

Primary Completion Date

February 14, 2019

Study Completion Date

February 14, 2019

Conditions

Contrast Medium

Interventions

DRUG

Iopromide (Ultravist, BAY86-4877)

Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.

Trial Locations (1)

Many Locations, Multiple Locations